时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Oxaliplatin-based neoadjuvant chemotherapy (NACT) is increasingly used in locally advanced colorectal cancer (CRC); however, early acquired resistance substantially limits its efficacy. We revealed an enrichment of therapy-induced senescence (TIS)-like phenotypes in short-term oxaliplatin-exposed CRC. Consistently, a similar upregulation …
对本项目的价值
参考价值：属「衰老细胞清除 / SASP 轴」方向；细胞衰老 / senolytics / SASP栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.8/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 Europe PMC / OpenAlex / Unpaywall 未提供可下载 OA 全文
原文题录
- 中文题名：治疗诱导的肿瘤衰老经 ADORA1 依赖的棕榈酸代谢重编程驱动结直肠癌奥沙利铂耐药
- 英文标题：Therapy-induced tumour senescence drives oxaliplatin resistance via ADORA1-dependent palmitic acid metabolic reprogramming in colorectal cancer.
- 期刊与标识：Oncogene · PMID 42977749 · DOI 10.1038/s41388-026-04024-z